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Background and aim Serum pepsinogen I (PGI) and pepsinogen II (PGII) are noninvasive parameters in the detection of
atrophic gastritis. The diagnostic add-on value of serum gastrin-17 (G-17) remains uncertain. The aim of this study was to assess
the stability of these serum parameters over time and to evaluate the influence of clinical factors, such as upper gastrointestinal
(GI) endoscopy and bowel cleansing, on serum PGI, PGII, and G-17 assessment.
Patients and methods A prospective study was carried out in healthy individuals and patients. For the stability analyses, the
plasma and serum samples from 23 individuals were processed at different time points with and without the addition of a
stabilizer. Ten patients were included to evaluate the influence of upper GI endoscopy and 18 patients to evaluate the effect of
bowel cleansing before colonoscopy.
Results PGI, PGII, and G-17 levels were not statistically different in the serum and plasma. PGI and PGII serum levels were
stable over time. G-17 is associated with time-dependent degradation (P=0.0001). The addition of the G-17 stabilizer showed
no improvement in stability. Upper GI endoscopy and bowel preparation before colonoscopy were associated with minimal
variations in PGI and PGII, whereas G-17 showed patient-specific alterations.
Conclusion PGI and PGII serum levels are stable over time. However, G-17 stability is strongly dependent on the time of
processing and storage; therefore, samples for G-17 analysis need to be processed no later than 6 h after blood collection.
Upper GI endoscopy and colonoscopy preparation lead to minimal nonsignificant changes in basal PGI, PGII, and G-17 levels.
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Introduction
Serum pepsinogen I (PGI) and pepsinogen II (PGII) are
proenzymes of pepsin, an endoproteinase of gastric juice,
and they are related to the histologic and functional status
of the gastric mucosa. PGI is secreted mainly by chief cells
in the fundic mucosa, whereas PGII is also secreted by the
pyloric glands and the proximal duodenal mucosa.
PGI and PGII are established noninvasive tools for the
detection of severe chronic atrophic gastritis (CAG) [1,2].
This feature is characterized by hypoachloridria because of
loss of appropriate gastric glands; therefore, there is a
decrease in serum PGI, PGII, and PGI/PGII ratio [1–4].
It is still questioned whether the additional determina-
tion of gastrin-17 (G-17) would increase the diagnostic
accuracy. According to a recent meta-analysis on 894
patients and 1950 controls, G-17 is useful in the diagnosis
of CAG and provides a better positive predictive value [5].
The serum test panel consisting of G-17, PGI, and
Helicobacter pylori-IgG was shown to be in significant
agreement with the endoscopic and histological findings in
CAG [6]. The correlation of serum pepsinogens with his-
tology was strengthened in a 12-year clinico-pathological
follow-up study in which gastritis staging was performed
along a scale of progressively severe atrophic gastritis,
from the lowest (OLGA stage 0) to the highest (OLGA
stage IV) and serology [7]. This led to the proposal of
serum pepsinogens as risk assessment markers for gastric
cancer [8–10]. However, a recent multicenter-blinded
study discouraged the use of PGI, PGII, G-17, and
H. pylori-IgG in the serological diagnosis of CAG [11].
The reasons for the discordant results were suggested to be
as follows: (a) assessments of PGs and G-17 are influenced
by intake of proton pump inhibitor, (b) different dynamics
and values in plasma/serum levels if samples were collected
either in the fasting or the postprandial state [12–14].
Therefore, it is crucial to document precisely the time
points and under which conditions the blood samples are
collected. Age and sex did not apparently seem to influence
PGI, PGII, and G-17 assessment [15]. Serum and plasma
are suitable biological samples for biomarkers [16].
However, in plasma or serum, biological molecules may be
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subject to proteolytic degradation caused by intrinsic
peptidase activities [17].
The data on the possible influence of preanalytical
factors as well as on endoscopy-related effects on the
measurement of PGI, PGII, and G-17 in serum are lacking.
The aim of the present study was to test the stability of
PGI, PGII, and G-17 over time and to evaluate the influ-
ence of endoscopy-related conditions on serum PGI, PGII,
and G-17 assessment. The rationale was to check whether
any chemical (4 l bowel cleansing intake) and mechanical
(e.g. biopsy sampling, endoscopy, gastric air insufflation)
stimulations may lead to changes in serum concentrations
of PGI, PGII, and G-17.
Patients and methods
Ethical statement
The study was approved by the local Ethics Committee
(number 80/11). All investigations were performed at
the Department of Gastroenterology, Hepatology and
Infectious Diseases at Otto-von-Guericke University
Magdeburg (Germany), in 2015. All study participants
provided a written informed consent.
Study design
Evaluation of stability
The stability of serum biomarkers (PGI, PGII, and G-17)
was evaluated in serum and plasma of 23 individuals:
healthy individuals and patients undergoing upper gas-
trointestinal (GI) endoscopy for dyspeptic symptoms. All
participants provided 20ml of peripheral blood samples
divided into one plasma and three serum aliquots, 5 ml
each. Serum and plasma samples were centrifuged at dif-
ferent time points (T0=within 30min, T6=6 h, and
T24=24 h, overnight) following the sample collection,
with and without the addition of a G-17 stabilizer (Biohit
Oyj, Helsinki, Finland).
Endoscopy-related factors
Upper gastrointestinal endoscopy: In a second step, the
influence of endoscopy-related factors on serum biomarkers
was investigated. PGI, PGII, and G-17 were determined in
blood samples obtained within 30min before and 30min
(5ml each) after the endoscopic procedure of patients
requiring upper GI endoscopy for dyspeptic symptoms.
Upper GI endoscopy was performed between 08.00 and
12.00 h in the morning, after an overnight fast, using
Olympus (Olympus Europe, Hamburg, Germany) and
Fujifilm (Fujifilm Europe, Düsseldorf, Germany) endo-
scopes. Sedation was performed either with Propofol and/or
Midazolam according to the German Guidelines [18].
Bowel cleansing: To evaluate the impact of colonoscopy
preparation on serum PGI, PGII, and G-17 values, we
determined these biomarkers in blood samples of patients
admitted in our department and undergoing colonoscopy
for different indications. Blood samples were obtained after
an overnight fast at two different time points, that is 1 day
before and the day on which colonoscopy was scheduled
before endoscopic investigation was performed. All patients
underwent colonoscopy preparation with a solution
containing Macrogol 3350, sodium sulfate, sodium
bicarbonate, sodium chloride, and potassium chloride in
split doses of 2 l in the evening and 2 l in the morning.
Assessment of pepsinogen I, pepsinogen II, and gastrin-
17 in serum and plasma: Blood samples were centrifuged
(2000g at 4°C for 10min) and stored at − 80°C, with and
without the addition of 25 µl of a G-17 stabilizer (Biohit
Oyj), at different time points (T0=within 30min, T6=6 h
and T24= 24 h, overnight) using an enzyme-linked immu-
nosorbent assay (Biohit Oyj) according to manufacturers’
instructions.
Statistical analysis: All statistical analyses were carried
out using Graph Pad Prism Pro, version 6.0 (GraphPad
Software Inc., La Jolla, California, USA). For groupwise
comparison of parametrical data, we used Student’s t-test
and the Wilcoxon-test for comparison of two groups and
Friedman’s test for nonparametrical comparisons of three
or more groups with Dunn’s multiple comparisons post-
test. For all tests, a two-sided P less than 0.05 was con-
sidered to be statistically significant.
Results
Stability of pepsinogen I, pepsinogen II, and gastrin-17
Overall, serum and plasma samples obtained from 23 indi-
viduals (male : female=10 : 13; mean age± SD 53.3±19.4)
were examined for the stability analysis of PGI, PGII,
and G-17.
Overall, PGI and PGII were stable over a period of 24h
(PGI mean values±SD:T0 166.9±114.1 µg/l, T6 164.6±108.8
µg/l, T24=166.6±113.3 µg/l, Friedman’s test P>0.9; PGII
mean values±SD: T0 14.1±7.9 µg/l, T6 14.3±8.2 µg/l, T24
14.0±8.1 µg/l, Friedman’s test P=0.8), whereas serum
values of G-17 showed a statistically significant decrease over
time (G-17 mean values±SD: T0 12.0±19.5 pmol/l, T6
10.7±17.8 pmol/l, T24 8.2±14.8 pmol/l, Friedman’s test
P=0.0001). The relative decrease in the G-17 value was 20.9
and 60.7% at 6 and 24h after blood collection, respectively
(Fig. 1).
Furthermore, we evaluated the difference between serum
and plasma samples. PGI, PGII, and G-17 levels were com-
parable between serum and plasma (PGI mean values±SD in
serum vs. plasma: 191.5±163.4 µg/l vs. 192.7±163.9 µg/l;
Wilcoxon-test P=0.6; PGII mean values±SD: serum
33.4±58.5 µg/l vs. plasma 31.5±52.3 µg/l; Wilcoxon-test
P=0.4; G-17 mean values±SD: serum 25.1±36.1 pmol/l vs.
plasma 25.1±37.3 pmol/l; Wilcoxon-test P=0.2) (Table 1
and Fig. 2).
Finally, we evaluated whether the addition of a stabilizer
or the time point of centrifugation may influence biomarker
assessment. The use of the G-17 stabilizer has been pro-
posed by the manufacturer to improve G-17 stability. The
addition of the G-17 stabilizer had no effect on the serum
and plasma stability of PGI and PGII (PGI Friedman’s test
P=0.4; PGII Friedman’s test P=0.1). However, the addi-
tion of the G-17 stabilizer improved the G-17 stability in
plasma (G-17 mean values ± SD plasma without a stabilizer
25.0±37.3 pmol/l vs. plasma with a stabilizer 27.4±41.4;
Wilcoxon-test P=0.007), but not in serum (G-17 mean
values± SD: serum without a stabilizer 25.1±36.1 pmol/l
vs. serum with a stabilizer 26.5±38.7 pmol/l; Wilcoxon-
test P=0.5) (Table 1 and Fig. 2). The G-17 stabilizer did
not improve G-17 stability over time also in samples with
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immediate centrifugation (within 30min after sample col-
lection) and storage. Our results confirmed that G-17
assessment depends on the time of processing and storage.
Indeed, G-17 levels were decreased by 20.9 and 60.7% in
serum samples that were centrifuged and stored 6 and 24 h
after blood collection, respectively, and this was
independent of the addition of the stabilizer. For samples
that were centrifuged immediately, but further stored at
room temperature, the addition of the stabilizer was asso-
ciated with improved stability (95.8 vs. 82.8% after 6 h
and 78.9 vs. 54.0% after 24 h) compared with samples





































Fig. 1. The stability over time of serum PGI, PGII, and G-17 levels. (a) PGI (μg/l), (b) PGII (μg/l), and (c) G-17 (pmol/l); T0=within 30min, T6=6 h, T24= 24 h
(overnight). Friedman’s test for nonparametrical comparisons of three or more groups with Dunn’s multiple comparisons post-test. *P< 0.05. G-17, gastrin-17;
PGI, pepsinogen I; PGII, pepsinogen II.
Table 1. Impact of stabilizer on the stability of pepsinogen I, PGII, pepsinogen II, and gastrin-17 at T0 (within 30min from blood sample collection)
Serum (mean ±SD) Serum+ stabilizer (mean ±SD) Plasma (mean ±SD) Plasma+ stabilizer (mean ±SD) P value*
PGI (μg/l) 191.5 ± 163.4 191.6 ±158.5 192.7 ±163.9 187.4 ±149.5 0.4
PGII (μg/l) 33.4 ± 58.5 32.6 ±54.4 31.5 ±52.3 30.4.4 ±50.3 0.1
G-17 (pmol/l) 25.1 ± 36.1 26.5 ±38.7 25.1 ±37.3 27.5 ±41.4 0.03
G-17, gastrin-17; PGI, pepsinogen I; PGII, pepsinogen II.













































































Fig. 2. Difference in PGI, PGII, and G-17 levels between plasma and serum with and without a stabilizer. Assessment of plasma and serum for (a) PGI (μg/l),
(b) PGII (μg/l), and (c) G-17 (pmol/l) (μg/l). Friedman’s test for nonparametrical comparisons of three or more groups with Dunn’s multiple comparisons post-
test. *P<0.05. G-17, gastrin-17; PGI, pepsinogen I; PGII, pepsinogen II.
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Influence of endoscopy-related factors
Upper gastrointestinal endoscopy
The influence of endoscopy-related factors on serum PGI,
PGII, and G-17 was analyzed in the 10 patients under-
going upper GI endoscopy (male : female=4 : 6, mean
age ± SD 58.3 ± 19.4 years).
Upper GI endoscopy did not influence serum PGI (mean
values± SD: before 213.6±181.8 μg/l vs. after 212.8±189.5
μg/l; Wilcoxon-test P=0.16), PGII (mean values± SD:
before 40.3±65.8 μg/l vs. after 38.8±65.8 μg/l; Wilcoxon-
test P=0.1), and G-17 (mean values± SD: before
32.2±38.9 pmol/l vs. after 29.7±34.0 pmol/l; Wilcoxon-test
P>0.99) assessment (Table 2).
Overall, no changes were observed for PGI and PGII
serum levels before and after upper GI endoscopy.
However, considerable patients-specific variations in
serum G-17 levels were observed with respect to endo-
scopic procedures. For instance, 30% of patients showed
an increase and 30% showed a decrease in G-17 levels
after upper GI endoscopy.
Bowel preparation for colonoscopy
Eighteen patients (N= 18, male : female= 14 : 4, mean
age ± SD: 66.6 ± 13.3) undergoing colonoscopy were
enrolled prospectively to assess the potential influence of
bowel cleaning on the assessment of gastric biomarkers.
Serum values of the analyzed biomarkers 1 day before and
on the day on which colonoscopy was scheduled were as
follows: PGI (mean values ± SD: 154.6 ±83.0 vs.
147.4 ±83.3 μg/l; Wilcoxon-test P= 0.9), PGII (mean
values ± SD: 10.9 ±6.0 vs. 10.5.4 ±6.1 μg/l; Wilcoxon-test
P=0.9), and G-17 (mean values ± SD: 13.3 ±17.2 vs.
16.6 ±14.8 pmol/l; Wilcoxon-test P=0.2) (Table 2). Bowel
preparation did not influence serum PGI and PGII values.
With respect to serum G-17, individual variations between
the two time points of blood collection were observed. In
particular, serum G-17 values increased in four (22.2%)
patients, decreased in four (22.2%) patients, and remained
approximately the same in the remaining 10 (55.5%)
patients.
Discussion
Serum PGI and PGII are proposed as noninvasive biomarkers
for the detection of gastric atrophy in clinical practice. There
continue, however, to be uncertainties related to the metho-
dology, the stability, and reproducibility of these parameters
depending on the timing, sampling, and processing of






















































Fig. 3. The role of G-17 stabilizer addition before and after sample processing. (a) Centrifugation and storage, with or without the addition of a stabilizer
immediately before sample processing; T0=within 30min, T6=6 h, T24= 24 h (overnight). (b) Addition of a stabilizer after sample processing and storage.
T0=within 30min, T6= 6 h, T24=24 h (overnight). %, Percentage of variation in G-17 serum levels; Stab, G-17 stabilizer.
Table 2. Influence of upper gastrointestinal endoscopy and bowel cleansing on PGI, pepsinogen I, pepsinogen II, gastrin-17 assessment
Upper GI endoscopy (N=10) Bowel cleaning (N=18)
Before (mean ±SD) After (mean ±SD) P value* Before (mean±SD) After (mean ±SD) P value*
PGI (μg/l) 213.6 ±118.8 212.8 ±189.5 0.16 154.6 ± 83.0 147.4 ±83.3 0.9
PGII (μg/l) 40.3 ±65.9 38.8 ±65.3 0.1 10.9 ± 6.0 10.5 ±6.1 0.9
G-17 (pmol/l) 32.2 ±38.7 29.8 ±34.0 >0.99 13.3 ± 17.2 16.6 ±14.9 0.2
G-17, gastrin-17; GI, gastrointestinal; PGI, pepsinogen I; PGII, pepsinogen II.
*Wilcoxon-test, P<0.05.
A prospective study Goni et al. www.eurojgh.com 1343
Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
conditions that might have an influence on the determination
of these parameters. The main reason we tested serum PGI,
PGII, and G-17 levels before and after upper GI endoscopy
and in relation to bowel cleansing has been a practical one as
blood for gastric ‘screening’ endoscopy-related procedures is
often taken in the context of. The rationale was to check
whether any chemical (4 lbowel cleansing intake) and
mechanical (e.g. biopsy sampling, endoscopy, gastric air
insufflation) stimulation might lead to changes in serum
concentrations of PGI, PGII, and G-17.
Stability over time of pepsinogen I, pepsinogen II, and
gastrin-17
The stability of the biomarker, reproducibility, and sim-
plicity of the method are crucial factors for their determi-
nation and translation into the clinical practice [16]. Our
results confirmed that PGI, PGII, and G-17 levels showed
no differences in serum versus plasma assessment.
Moreover, we showed that PGI and PGII levels are not
influenced by preanalytical factors including storage time
at different time points and centrifugation, and can
therefore be considered as good biomarkers.
Recently, a study including 91 patients analyzed the
value of PGI, PGII, and G-17 as noninvasive biomarkers in
the diagnosis of atrophic gastritis [11]. In particular, G-17,
according to the authors, did not provide any additional
diagnostic value. One of the potential explanations may be
related to the stability of G-17 in serum samples over time.
Indeed, we show that G-17 serum and plasma levels
undergo substantial degradation depending on the pro-
cessing and storage of the samples. Compared with the
samples processed immediately with the best possible time/
efficiency following blood collection, a serum level varia-
tion of 20.9% was observed when samples were processed
and stored no later than 6 h after blood sampling. The
variation in G-17 in serum reached up to 60.7% for
samples centrifuged and stored within 24 h after blood
collection independent of the addition of the stabilizer.
Therefore, we suggest that in real-life settings, the sample
processing should be documented and processed ideally
within 30–60min. Although this time interval is usually
not achievable in ‘real-life’ settings, the processing should
be no later than within 6 h. G-17 degradation is one of the
most important limitations of the biomarker in clinical
practice. The addition of the G-17 stabilizer did not
improve of G-17 stability over time also in samples sub-
jected to immediate centrifugation (within 30min after
sample collection) and storage. The majority of previous
studies available do not specify the time point of cen-
trifugation, processing, and storage time after sample
collection. Our findings suggest that time of sample col-
lection and determination should be documented carefully
and specified to obtain reliable results. As also the addition
of a stabilizer to the serum sample was not effective in
antagonizing G-17 degradation over time, the degradation
dynamics would allow for normalization of the G-17 levels
by a formula that considers time point of sampling and
degradation in percentage per hour.
The influence of gastrointestinal endoscopy
Several investigations have reported on a positive asso-
ciation between H. pylori infection and increased risk for
the development of colonic neoplasms [19–24]. This has
led to the proposal of combining colorectal cancer
screening with PGI, PGII, and G-17 assessment. Our study
showed that upper GI endoscopy and bowel preparation
did not influence serum PGI and PGII values. However,
endoscopy procedures and bowel cleansing led to slight
but not significant changes in G-17 levels, associated with
an intraindividual variation in 30% of the patients. G-17
variations may be because of mechanical stimulation of the
gastric mucosa resulting from bowel cleaning, or gastric
air insufflation, pH-changes, or even biopsy sampling
during upper GI endoscopy. Therefore, because of varia-
tions in gastric serum parameters, especially G-17
following endoscopy or bowel cleansing preparation, we
stress that blood sampling should be performed only
during the fasting state before endoscopic or other inter-
ventional procedures on the stomach and the bowel.
Conclusion
PGI and PGII serum levels are stable over time and their
assessment is not influenced by preanalytical factors such
as time of centrifugation, storage, or addition of stabilizer.
In contrast, G-17 stability was strongly dependent on time
to processing and storage and addition of the G-17 stabi-
lizer does not provide an additional benefit if the samples
are frozen following centrifugation.
In future clinical studies, it is advised to take blood
samples in the fasting state and not following endoscopic
procedures and bowel cleansing. The timing of sample
collection and determination should be registered and
specified to provide reproducible results.
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